Australia's most trusted
source of pharma news
Thursday, 04 September 2025
Posted 1 September 2025 PM
Ipsen’s fibrodysplasia ossificans progressiva treatment Sohonos was added to PBS for the first time this morning as Sanofi scored a trifecta win for its immunology star Dupixent.
Fibrodysplasia ossificans progressiva is an ultra-rare, genetic condition that causes bone to form in muscles, tendons, and other soft tissues. This extra growth makes it hard to move and perform everyday tasks. Even minor injuries can trigger painful flare-ups and new bone formation.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.